Pipeline
Our pipeline reflects Endeavor’s commitment to advancing innovative therapies for fibrotic diseases with high unmet need. Guided by insights into fibrosis biology and informed by clinical proof of concept in idiopathic pulmonary fibrosis (IPF), we are developing programs designed to address the underlying mechanisms that drive disease progression.
Endeavor BioMedicines’ Pipeline
Taladegib
IPF
Hedgehog Pathway Inhibitor
Undisclosed Program
Hedgehog Pathway Inhibitor
Undisclosed Program
Hedgehog Pathway Inhibitor
Primary and Multiple Secondary Endpoints Met in Phase 2b Trial
Endeavor BioMedicines announced that its Phase 2b WHISTLE-PF trial evaluating taladegib (ENV-101), an investigational Hedgehog signaling pathway inhibitor, met its primary endpoint and multiple secondary endpoints in patients with idiopathic pulmonary fibrosis (IPF). The results reinforce taladegib’s potential to reverse the course of IPF.
